Article
A fully human monoclonal antibody that has been found to inhibit interleukin-17A may significantly improve moderate-to-severe plaque psoriasis, according to new phase 2 study data recently released.
The Weekly Roundup: February 10-14
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Daily Derm Times: February 14, 2025
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Nektar's Jonathan Zalevsky, PhD, Dives Into Rezpegaldesleukin Fast Track Designation for Atopic Dermatitis
Tailoring Atopic Dermatitis Treatment to Meet Patient Needs